RxDoctor Payments Data

Donald Hudak, MD

Ophthalmic Plastic and Reconstructive Surgery · Batesville, INNPI 1396709234

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Amgen at 51.8% of the total.

$2,548in general payments, 2019–2025

Across 69 payments — averaging $36.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Alcon$356
  • Tarsus Pharmaceuticals, Inc.$236
  • Sun Pharmaceutical Industries Inc.$150
  • Rxsight Inc$121
  • AbbVie$101
  • plus $263 from 10 others

What the payments were for

  • Food & beverage$2,548100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$179,541
Medicare patients
249
Services billed
2,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base285$3,435
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$517
Prednisolone Acetate16$400
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha37$394
Cephalexin57$295
Minocycline Hcl39$238
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate13$146
Methylprednisolone20$110
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$90
Doxycycline Hyclate11$85
Prednisone18$45

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Batesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →